LCII reported Q4 FY2025 net sales of USD 932.7 million (+16%), with net income of USD 18.68 million (+96%) and diluted EPS of USD 0.77 (more than doubled). Adjusted net income was USD 21.65 million and adjusted diluted EPS was USD 0.89 (+138%), while adjusted EBITDA rose to USD 70.14 million (+53%), or 7.5% of net sales. Q4 operating profit was USD 35.36 million and operating margin expanded to 3.8% from 2.0%, including USD 3.9 million of restructuring costs tied to the closure of LCII’s glass operations in Ireland. For FY2025, LCII posted net sales of USD 4.12 billion (+10%), net income of USD 188.25 million (+32%) and diluted EPS of USD 7.57 (+35%). Adjusted net income was USD 185.39 million and adjusted diluted EPS was USD 7.46 (+33%); adjusted EBITDA increased to USD 408.25 million (+19%), or 10% of net sales, and operating margin improved to 6.8% from 5.8%. Operating cash flow was USD 330.98 million, and LCII returned USD 243 million to shareholders via dividends and share repurchases in 2025. Business highlights included towable RV content per unit of USD 5,670 (+11%) and top five new innovative products projected at a USD 225 million annualized sales run rate. LCII also cited transportation market expansion through the acquisitions of Trans Air and Freedman Seating Company, and ended 2025 with USD 818 million of liquidity (USD 222.62 million cash and USD 595.2 million revolver availability). For 2026, LCII forecast revenue of USD 4.2 billion to USD 4.3 billion, operating margin of 7.5% to 8.0%, and adjusted EPS of USD 8.25 to USD 9.25.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LCI Industries published the original content used to generate this news brief on February 18, 2026, and is solely responsible for the information contained therein.
Comments